-
The FDA approved a drug that slowed the growth of Alzheimer’s.
US’ Food and Drug Administration is expected to decide this week whether to give accelerated approval to lecanemab, an experimental Alzheimer’s drug, according to Biogen and Eisai. Lecanemab has been tested in a phase III clinical trial to see if it would stop brain shrinkage in Alzheimer’s patients. Earlier, three people had died after receiving…
-
Is lecanemab the key to changing the course of Alzheimer’s disease?
US’ Food and Drug Administration (FDA) is considering an accelerated approval for a drug to treat Alzheimer’s disease. Leqembi, developed by Biogen and Eisai, reduced marker of amyloid in Alzheimer’s patients’ brains and was associated with less decline in cognitive function than a placebo. The drug is currently being tested in a Phase 3 clinical…